Neutralization of Clostridium difficile toxin A using antibody combinations

The pathogenicity of Clostridium difficile (C. difficile) is mediated by the release of two toxins, A and B. Both toxins contain large clusters of repeats known as cell wall binding (CWB) domains responsible for binding epithelial cell surfaces. Several murine monoclonal antibodies were generated against the CWB domain of toxin A and screened for their ability to neutralize the toxin individually and in combination. Three antibodies capable of neutralizing toxin A all recognized multiple sites on toxin A, suggesting that the extent of surface coverage may contribute to neutralization. Combination of two noncompeting antibodies, denoted 3358 and 3359, enhanced toxin A neutralization over saturating levels of single antibodies. Antibody 3358 increased the level of detectable CWB domain on the surface of cells, while 3359 inhibited CWB domain cell surface association. These results suggest that antibody combinations that cover a broader epitope space on the CWB repeat domains of toxin A (and potentially toxin B) and utilize multiple mechanisms to reduce toxin internalization may provide enhanced protection against C. difficile-associated diarrhea.

[1]  Herren Wu,et al.  The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. , 2009, Journal of molecular biology.

[2]  Christilyn P. Graff,et al.  Characterization of Inhibitory Anti-insulin-like Growth Factor Receptor Antibodies with Different Epitope Specificity and Ligand-blocking Properties , 2009, Journal of Biological Chemistry.

[3]  A. Lugovskoy,et al.  Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR , 2009 .

[4]  Julian I. Rood,et al.  Toxin B is essential for virulence of Clostridium difficile , 2009, Nature.

[5]  M. Rupnik.  Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. , 2008, FEMS microbiology reviews.

[6]  Sahana Bose,et al.  Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin , 2007, Nature Biotechnology.

[7]  Robert B. Mandell,et al.  Human Monoclonal Antibodies Directed against Toxins A and B Prevent Clostridium difficile-Induced Mortality in Hamsters , 2006, Infection and Immunity.

[8]  A. Tolstrup,et al.  Production of target‐specific recombinant human polyclonal antibodies in mammalian cells , 2006, Biotechnology and bioengineering.

[9]  M. Palcic,et al.  Carbohydrate recognition by Clostridium difficile toxin A , 2006, Nature Structural &Molecular Biology.

[10]  K. Ng,et al.  Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  B. E. Kimmel,et al.  Structural characterization of the cell wall binding domains of Clostridium difficile toxins A and B; evidence that Ca2+ plays a role in toxin A cell surface association. , 2005, Journal of molecular biology.

[12]  L. Mcfarland.  Alternative treatments for Clostridium difficile disease: what really works? , 2005, Journal of medical microbiology.

[13]  Yen-Ming Hsu,et al.  Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. , 2005, Biochemistry.

[14]  J. Marks.  Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization , 2004, Movement disorders : official journal of the Movement Disorder Society.

[15]  T. Monath,et al.  Clostridium difficile Vaccine and Serum Immunoglobulin G Antibody Response to Toxin A , 2003, Infection and Immunity.

[16]  T. Peláez,et al.  Reassessment of Clostridium difficile Susceptibility to Metronidazole and Vancomycin , 2002, Antimicrobial Agents and Chemotherapy.

[17]  H. Katinger,et al.  Neutralization Synergy of Human Immunodeficiency Virus Type 1 Primary Isolates by Cocktails of Broadly Neutralizing Antibodies , 2001, Journal of Virology.

[18]  M. Wilcox,et al.  Reduced susceptibility of Clostridium difficile to metronidazole. , 2001, The Journal of antimicrobial chemotherapy.

[19]  G. Palace,et al.  Analysis of the physicochemical interactions between Clostridium difficile toxins and cholestyramine using liquid chromatography with post-column derivatization. , 2001, Biochimica et biophysica acta.

[20]  E. Mylonakis,et al.  Clostridium difficile--Associated diarrhea: A review. , 2001, Archives of internal medicine.

[21]  C. Pothoulakis,et al.  Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[22]  C. Kelly,et al.  Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea , 2001, The Lancet.

[23]  C. Kelly,et al.  Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. , 2000, The New England journal of medicine.

[24]  T. Monath,et al.  Serum Antitoxin Antibodies Mediate Systemic and Mucosal Protection from Clostridium difficileDisease in Hamsters , 1999, Infection and Immunity.

[25]  D. Gerding,et al.  Clostridium difficile--associated diarrhea. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  J. Kink,et al.  Antibodies to Recombinant Clostridium difficile Toxins A and B Are an Effective Treatment and Prevent Relapse of C. difficile-Associated Disease in a Hamster Model of Infection , 1998, Infection and Immunity.

[27]  C. von Eichel-Streiber,et al.  The C-terminal ligand-binding domain of Clostridium difficile toxin A (TcdA) abrogates TcdA-specific binding to cells and prevents mouse lethality. , 1997, FEMS microbiology letters.

[28]  K. Aktories,et al.  Localization of the Glucosyltransferase Activity of Clostridium difficile Toxin B to the N-terminal Part of the Holotoxin* , 1997, The Journal of Biological Chemistry.

[29]  L. Hood,et al.  Rapid cloning of any rearranged mouse immunoglobulin variable genes , 1996, Immunogenetics.

[30]  C. Pothoulakis,et al.  A receptor decoy inhibits the enterotoxic effects of Clostridium difficile toxin A in rat ileum. , 1996, Gastroenterology.

[31]  K. Aktories,et al.  Monoglucosylation of low-molecular-mass GTP-binding Rho proteins by clostridial cytotoxins. , 1995, Trends in cell biology.

[32]  J. Chia,et al.  Baker's yeast as adjunctive therapy for relapses of Clostridium difficile diarrhea. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  H. Dyson,et al.  Gene synthesis, high-level expression, and mutagenesis of Thiobacillus ferrooxidans rusticyanin: His 85 is a ligand to the blue copper center. , 1995, Biochemistry.

[34]  C. Fiorentini,et al.  Bacterial protein toxins acting on the cell cytoskeleton. , 1994, The new microbiologica.

[35]  S. Morrison,et al.  Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. , 1992, Journal of immunological methods.

[36]  T. Wilkins,et al.  Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A , 1992, Infection and immunity.

[37]  S. Binion,et al.  Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate , 1991, Infection and immunity.

[38]  G. Corthier,et al.  Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A , 1991, Infection and immunity.

[39]  T. Wilkins,et al.  Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y , 1991, Infection and immunity.

[40]  John L. Johnson,et al.  Vaccination against lethalClostridium difficile enterocolitis with a nontoxic recombinant peptide of toxin A , 1990, Current Microbiology.

[41]  J. Hotz.  [Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study]. , 1990, Zeitschrift fur Gastroenterologie.

[42]  T. Wilkins,et al.  Clostridium difficile: its disease and toxins , 1988, Clinical Microbiology Reviews.

[43]  B. Goldin,et al.  SUCCESSFUL TREATMENT OF RELAPSING CLOSTRIDIUM DIFFICILE COLITIS WITH LACTOBACILLUS GG , 1987, The Lancet.

[44]  J. Tóth,et al.  Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies , 1986, Infection and immunity.

[45]  G. Clark,et al.  Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc , 1986, Infection and immunity.

[46]  C. Phelps,et al.  Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A , 1985, Journal of clinical microbiology.

[47]  R. Wagner,et al.  Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule , 1984, Infection and immunity.

[48]  L. Gonzales.  Clostridium difficile , 2010, Methods in Molecular Biology™.

[49]  E. Kuijper,et al.  Emergence of Clostridium difficile-associated disease in North America and Europe. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[50]  C. Kelly,et al.  Clostridium difficile : Specific Pathogens , 2001 .

[51]  J. García,et al.  Versatility of choline-binding domain. , 1998, Microbial drug resistance.

[52]  C. von Eichel-Streiber,et al.  Clostridium difficile toxin A carries a C-terminal repetitive structure homologous to the carbohydrate binding region of streptococcal glycosyltransferases. , 1990, Gene.

[53]  P. Walker,et al.  Active and passive immunization to protect against antibiotic associated caecitis in hamsters. , 1983, Developments in biological standardization.